Chair in Public Health, Honorary Consultant Cardiologist
Imperial College London, UK
A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Kausik Ray is also a member of the British Cardiovascular Society and European Atherosclerosis Society. Professor Ray has been the national lead investigator, served on the committees or been PI for several major medical trials, including T-EMERGE 8, SOLID TIMI 52, SAVOR TIMI 54, DAL OUTCOMES II, DAL-ACUTE, ODYSSEY OUTCOMES, DECLARE TIMI 58, CAMELIA TIMI 61 and THEMIS and is currently involved in 8 ongoing trials.
Professor Ray’s research interests have focused on the prevention and reduction of coronary events, preventive cardiology and diabetes. He has investigated the early benefits of statin therapy, the advantages of more/less intensive glycaemic control, and the risks/benefits of aspirin therapy. These have influenced AHA/ACC and ESC guidelines. His work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. He continues to investigate the role of lipids, lipoproteins, diabetes, inflammation and thrombosis and coronary events. He has received numerous research grants including from the British Heart Foundation and the Wellcome Trust Project and is part of the EAS Consensus panel. Currently Professor Ray leads the EAS FH Studies collaboration and is the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250 000 people in London. Whilst Prof of CVD Prevention at St George’s University of London he developed and led Integrated Care Pathway for patients with ACS, the first electronic pathway for such patients in the world..
Professor Ray has published his research in numerous journals including the NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal which have attracted approximately 12 000 citations.
H index of 40 i10 of 69 and more than 11,900 citations overall
Ray KK, Cannon CP, Cairns R, Tonkin AJ, Sacks F, Jackson G, McCabe C, Braunwald E. The early and late benefits of high dose atorvastatin in patients with acute coronary syndromes. Results from the PROVE IT-TIMI 22 trial. JACC 2005; 46 (8), 1405-1410
Wiviott S, Cannon CP, Morrow D, Ray KK, Pfeffer M, Braunwald E. Can LDL be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: A PROVE IT - TIMI 22 substudy JACC 2005; 46 (8), 1411-1416
Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD Braunwald E, Gibson CM. Benefits of achieving the optional NCEP LDL-C goals in elderly patients with ACS. European Heart Journal 2006; 27 (19), 2310-2316
Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Clinical utility of apo B/AI, Ctotal cholesterol/ HDL and non-HDL cholesterol or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: Results from PROVE IT-TIMI 22. ATVB 2009 , 29 (3), 424-430
Emerging Risk Factors Collaboration. Interplay of Triglycerides, HDL-C and non-HDL-C concentrations on risk of CHD and stroke. Individual data analysis of 291 107 participants from 66 cohorts. JAMA 2009, 302, 1993-2000
Emerging Risk Factors Collaboration. Lipoprotein (a) concentration and the risk of CHD, stroke and non-vascular mortality. Individual data analysis of 121 944 participants from 34 cohorts. JAMA 2009, 302, 412-423
Emerging Risk Factors Collaboration. C reactive protein concentration and the risk of CHD, stroke and non-vascular mortality. Individual data analysis of 126 338 participants from 48 studies Lancet 2010, 375, 132-40
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, Seshasai SRK, McMurray JJ, Freeman D, Jukema W, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis B, Pressel SL, Marchioli R, Maggioni MRM, Tavazzi L, Tognoni G, Kjekshus J, Pedersen T, Cook T, Gotto AM, Nakamura H, Ray KK, Ford I. Statins and the risk of incident diabetes: a collaborative meta-analysis of thirteen randomised statin trials involving 91,141 participants. Lancet 2010, 375, (9716), 735-42
Ray KK, Seshasai SR, Erqou S, Sever P, Jukema W, Ford I, Sattar N. Statins and all cause mortality reduction in high risk primary prevention a meta-analysis of 11 randomised trials involving 65 299 participants. Archives of Internal Medicine 2010; 170(12), 1024-1031
Emerging Risk Factors Collaboration. Diabetes, fasting glucose and risk of vascular disease. Lancet 2010, 375, (3733), 2215-22
Preiss, D., Seshasai, S. R. K., Welsh, P., Murphy, S. A., Ho, J. E., Waters, D. D., Ray, KK (2011, June 22). Risk of Incident Diabetes With Intensive-Dose Compare With Moderate-Dose Statin Therapy A Meta-analysis. JAMA, 2011, 305(24), 2556 2564.
Benjamin M. Scirica, M.D., M.P.H., Deepak L. Bhatt, M.D., M.P.H., Eugene Braunwald, M.D., P. Gabriel Steg, M.D., Jaime Davidson, M.D., Boaz Hirshberg, M.D., Peter Ohman, M.D., Robert Frederich, M.D., Ph.D., Stephen D. Wiviott, M.D., Elaine B. Hoffman, Ph.D., Matthew A. Cavender, M.D., M.P.H., Jacob A. Udell, M.D., M.P.H., Nihar R. Desai, M.D., M.P.H., Ofri Mozenson, M.D., Darren K. McGuire, M.D., Kausik K. Ray, M.D., Lawrence A. Leiter, M.D., and Itamar Raz, M.D. for the SAVOR-TIMI 53 Steering Committee and Investigators . Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine 2013 Oct 3;369(14):1317-26.
Swerdlow D,….. Ray KK……Sattar N. HMG coenzyme A reductase inhibition, Type 2 diabetes and bodyweight: evidence from genetic analyses and randomised trials Lancet 2014 Sep 24th, pii: S0140-6736(14)61183-1. doi: 10.1016/S0140-6736(14)61183-1. [Epub ahead of print]
Kausik Kumar Ray is currently Professor of Public Heath, Department of Public Health and Primary Care, School of Public Health, Imperial College London. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.